The 1st prize winning paper, “Incorporating Real Option Value in Valuing Innovation: A Way Forward,” by Meng Li, ScM, PhD and Louis P. Garrison, PhD introduces a “minimal modeling” approach to assess real option value (ROV) in HTA without full cost-effectiveness model. The method leverages publicly available data to estimate ROV, highlighting its impact on cost, value estimates, and cost-effectiveness ratios. An analysis of ipilimumab for metastatic melanoma demonstrates ROV’s significant influence on value assessment.
